Pay in 4 interest-free payments of $5.88 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
and global data from the American Heart Association
Over time, sleep deprivation builds up, and can severely impact your emotional regulation
Lilly's retatrutide phase 3 results: 28.3% body weight loss on highest dose May 2026 Eli Lilly's phase 3 results for retatrutide show striking efficacy in obesity treatment: 28.3% body weight loss on the highest dose over 80 weeks approximately 70 lbs on average 45% of participants lost 30% or more of their body weight 65% on the top dose were no longer clinically obese Even the lowest 4mg dose delivered 19% weight loss with fewer dropouts than placebo Retatrutide is a triple-agonist targeting GIP, GLP-1, and glucagon receptors versus one receptor for semaglutide and two for tirzepatide (Mounjaro/Zepbound)
Understanding the evidence-based answer to this concern is essential for informed treatment decisions
